Gastroenterology Associates of Central Georgia

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis	Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	Phase 3	2026-10-02	NCT06588855
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis	Metabolic Dysfunction Associated Steatohepatitis	Recruiting	Phase 3	2026-10-01	NCT06632457
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis	Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder	Recruiting	Phase 3	2026-10-01	NCT06632444
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease	Moderately to Severely Active Crohns Disease	Recruiting	Phase 3	2026-09-16	NCT06819878
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	Phase 3	2026-09-14	NCT06589986

Clinical trials